Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The INN global nomenclature of biological medicines: A continuous challenge.

Robertson JS, Chui WK, Genazzani AA, Malan SF, López de la Rica Manjavacas A, Mignot G, Thorpe R, Balocco R, Rizzi M.

Biologicals. 2019 Jul;60:15-23. doi: 10.1016/j.biologicals.2019.05.006. Epub 2019 May 23. Review.

2.

β2-adrenergic stimulation of dendritic cells favors IL-10 secretion by CD4+ T cells.

Hervé J, Haurogné K, Bacou E, Pogu S, Allard M, Mignot G, Bach JM, Lieubeau B.

Immunol Res. 2017 Dec;65(6):1156-1163. doi: 10.1007/s12026-017-8966-3.

PMID:
29134568
3.

β2-adrenoreceptor stimulation dampens the LPS-induced M1 polarization in pig macrophages.

Bacou E, Haurogné K, Allard M, Mignot G, Bach JM, Hervé J, Lieubeau B.

Dev Comp Immunol. 2017 Nov;76:169-176. doi: 10.1016/j.dci.2017.06.007. Epub 2017 Jun 17.

PMID:
28633932
4.

Acute social stress-induced immunomodulation in pigs high and low responders to ACTH.

Bacou E, Haurogné K, Mignot G, Allard M, De Beaurepaire L, Marchand J, Terenina E, Billon Y, Jacques J, Bach JM, Mormède P, Hervé J, Lieubeau B.

Physiol Behav. 2017 Feb 1;169:1-8. doi: 10.1016/j.physbeh.2016.11.012. Epub 2016 Nov 17.

PMID:
27867043
5.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

6.

Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.

Mignot G, Hervieu A, Vabres P, Dalac S, Jeudy G, Bel B, Apetoh L, Ghiringhelli F.

PLoS One. 2014 Aug 29;9(8):e105907. doi: 10.1371/journal.pone.0105907. eCollection 2014.

7.

Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells.

Derangère V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Végran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rébé C.

Cell Death Differ. 2014 Dec;21(12):1914-24. doi: 10.1038/cdd.2014.117. Epub 2014 Aug 15.

8.

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rébé C, Dérangère V, Ryffel B, Kato M, Prévost-Blondel A, Ghiringhelli F, Apetoh L.

Nat Immunol. 2014 Aug;15(8):758-66. doi: 10.1038/ni.2925. Epub 2014 Jun 29.

PMID:
24973819
9.

Immune ambivalence: The schizophrenic bleomycin.

Mignot G, Bugaut H, Ghiringhelli F.

Oncoimmunology. 2013 Sep 1;2(9):e25737. Epub 2013 Jul 23.

10.

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L.

Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.

11.

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Rébé C, Apetoh L, Ghiringhelli F, Mignot G.

PLoS One. 2013 Jun 7;8(6):e65181. doi: 10.1371/journal.pone.0065181. Print 2013.

12.

Dacarbazine mediate antimelanoma effects via NK cells.

Hervieu A, Mignot G, Ghiringhelli F.

Oncoimmunology. 2013 Apr 1;2(4):e23714.

13.

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

Berger H, Végran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangère V, Chevriaux A, Rébé C, Ryffel B, Pot C, Hichami A, Desvergne B, Ghiringhelli F, Apetoh L.

Cancer Res. 2013 Jun 15;73(12):3578-90. doi: 10.1158/0008-5472.CAN-12-4018. Epub 2013 Apr 25.

14.

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F.

Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2.

PMID:
23202296
15.

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G.

J Invest Dermatol. 2013 Feb;133(2):499-508. doi: 10.1038/jid.2012.273. Epub 2012 Sep 6.

16.

Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.

Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, Zitvogel L, Kepp O, Kroemer G.

Sci Transl Med. 2012 Jul 18;4(143):143ra99. doi: 10.1126/scitranslmed.3003807.

17.

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rébé C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roché H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F.

Ann Oncol. 2012 Oct;23(10):2552-61. Epub 2012 Mar 19.

PMID:
22431701
18.

Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rébé C, Ghiringhelli F.

Immunity. 2012 Mar 23;36(3):362-73. doi: 10.1016/j.immuni.2011.12.019. Epub 2012 Mar 8.

19.

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G.

Science. 2011 Dec 16;334(6062):1573-7. doi: 10.1126/science.1208347.

20.

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.

Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F.

Br J Cancer. 2011 Jul 26;105(3):366-71. doi: 10.1038/bjc.2011.261. Epub 2011 Jul 12.

21.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F.

J Pathol. 2011 Jul;224(3):389-400. doi: 10.1002/path.2866. Epub 2011 Mar 25.

PMID:
21437909
22.

Tumor exosome-mediated MDSC activation.

Mignot G, Chalmin F, Ladoire S, Rébé C, Ghiringhelli F.

Am J Pathol. 2011 Mar;178(3):1403-4; author reply 1404-5. doi: 10.1016/j.ajpath.2010.11.078. No abstract available.

23.

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Mourey E, Michel F, Cormier L, Ghiringhelli F.

Anticancer Res. 2010 Oct;30(10):4317-23.

PMID:
21036758
24.

[Myeloid-derived suppressor cells: a key player in cancer].

Chalmin F, Mignot G, Ghiringhelli F.

Med Sci (Paris). 2010 Jun-Jul;26(6-7):576-9. doi: 10.1051/medsci/2010266-7576. French. No abstract available.

25.

Human FOXP3 and cancer.

Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F.

Oncogene. 2010 Jul 22;29(29):4121-9. doi: 10.1038/onc.2010.174. Epub 2010 May 24. Review.

PMID:
20498631
26.

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F.

Cancer Res. 2010 Apr 15;70(8):3052-61. doi: 10.1158/0008-5472.CAN-09-3690. Epub 2010 Apr 13.

27.

Dual role of heat shock proteins as regulators of apoptosis and innate immunity.

Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C.

J Innate Immun. 2010;2(3):238-47. doi: 10.1159/000296508. Epub 2010 Mar 16. Review.

28.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.

Ladoire S, Arnould L, Mignot G, Coudert B, Rébé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F.

Breast Cancer Res Treat. 2011 Jan;125(1):65-72. doi: 10.1007/s10549-010-0831-1. Epub 2010 Mar 13.

29.

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rébé C, Ghiringhelli F.

J Clin Invest. 2010 Feb;120(2):457-71. doi: 10.1172/JCI40483. Epub 2010 Jan 19.

30.

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Nat Med. 2009 Oct;15(10):1170-8. doi: 10.1038/nm.2028. Epub 2009 Sep 20.

PMID:
19767732
31.

The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells.

Terme M, Mignot G, Ullrich E, Bonmort M, Minard-Colin V, Jacquet A, Schultze JL, Kroemer G, Leclerc C, Chaput N, Zitvogel L.

Cancer Res. 2009 Aug 15;69(16):6590-7. doi: 10.1158/0008-5472.CAN-08-4473.

32.

CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.

Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, Lauvau G, Zitvogel L, Martin F, Chauffert B, Yagita H, Solary E, Ghiringhelli F.

J Clin Invest. 2008 Nov;118(11):3751-61. doi: 10.1172/JCI35890. Epub 2008 Oct 1.

33.

Killer dendritic cells: IKDC and the others.

Bonmort M, Dalod M, Mignot G, Ullrich E, Chaput N, Zitvogel L.

Curr Opin Immunol. 2008 Oct;20(5):558-65. doi: 10.1016/j.coi.2008.04.006. Epub 2008 Jun 12. Review.

PMID:
18554881
34.

Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions.

Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, Jalil A, Louache F, Bulanova E, Geissman F, Ryffel B, Chaput N, Bulfone-Paus S, Zitvogel L.

J Immunol. 2008 Jun 15;180(12):7887-97.

35.

[IKDC: killer dendritic cells or antigen-presenting NK cells?].

Zitvogel L, Mignot G, Bonmort M, Ullrich E, Chaput N.

Med Sci (Paris). 2008 May;24(5):525-8. doi: 10.1051/medsci/2008245525. Review. French. No abstract available.

36.

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

Mignot G, Ullrich E, Bonmort M, Ménard C, Apetoh L, Taieb J, Bosisio D, Sozzani S, Ferrantini M, Schmitz J, Mack M, Ryffel B, Bulfone-Paus S, Zitvogel L, Chaput N.

J Immunol. 2008 May 15;180(10):6477-83.

37.

Cancer is not just a disease of a tissue: it is a host disease. How to reactivate host defense against tumors using conventional therapies of cancer?

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Mignot G, Ullrich E, Kroemer G, Zitvogel L.

Ann Endocrinol (Paris). 2008 Apr;69(2):151-2. doi: 10.1016/j.ando.2008.02.016. Epub 2008 Apr 16. No abstract available.

PMID:
18420177
38.

Immunogenicity of anthracyclines: moving towards more personalized medicine.

Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L.

Trends Mol Med. 2008 Apr;14(4):141-51. doi: 10.1016/j.molmed.2008.02.002. Epub 2008 Mar 18. Review.

PMID:
18353726
39.

Dendritic cells and innate defense against tumor cells.

Ullrich E, Ménard C, Flament C, Terme M, Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N, Zitvogel L.

Cytokine Growth Factor Rev. 2008 Feb;19(1):79-92. Epub 2007 Dec 26. Review.

PMID:
18155952
40.

Tumor stress, cell death and the ensuing immune response.

Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L.

Cell Death Differ. 2008 Jan;15(1):21-8. Epub 2007 Nov 9. Review.

41.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
42.

Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC).

Bonmort M, Ullrich E, Mignot G, Jacobs B, Chaput N, Zitvogel L.

Biochimie. 2007 Jun-Jul;89(6-7):872-7. Epub 2007 May 5. Review.

PMID:
17574720
43.

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.

Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Ménard C, Viaud S, Tursz T, Kroemer G, Zitvogel L.

Cancer Res. 2007 Feb 1;67(3):851-3. Review.

44.

Calreticulin exposure dictates the immunogenicity of cancer cell death.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G.

Nat Med. 2007 Jan;13(1):54-61. Epub 2006 Dec 24.

PMID:
17187072
45.

Prospects for exosomes in immunotherapy of cancer.

Mignot G, Roux S, Thery C, Ségura E, Zitvogel L.

J Cell Mol Med. 2006 Apr-Jun;10(2):376-88. Review.

46.

Increasing rate of sexual assaults by adults appearing before the Assize Court of Rennes, France, during 1987-1997.

Mignot G, Paysant F, Caubet A, Le Gueut M.

J Clin Forensic Med. 1998 Sep;5(3):135-7.

PMID:
15335534
47.

pH dependence of uranyl retention in a quartz/solution system: an XPS study.

Froideval A, Del Nero M, Barillon R, Hommet J, Mignot G.

J Colloid Interface Sci. 2003 Oct 15;266(2):221-35.

PMID:
14527444
48.

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G.

Therapie. 1999 Jul Aug;54(4):405-11. French.

PMID:
10667106
49.

[Outline of the problem of indices of therapeutic efficacy. 4. Expression of efficacy when the underlying illness is incurable. Study Group for the Indices of Efficacy].

Boissel JP, Cucherat M, Chatellier G, Buyse M, Li W, Boutitie F, Nony P, Gueyffier F, Haugh M, Mignot G.

Therapie. 1999 Sep-Oct;54(5):519-23. French.

PMID:
10667083
50.

[The problem of therapeutic efficacy indices. 2. Description of the indices].

Boissel JP, Buyse M, Cucherat M, Boutitie F, Gueyffier F, Chatellier G, Li W, Nony P, Haugh M, Mignot G.

Therapie. 1999 May-Jun;54(3):309-14. French.

PMID:
10500443

Supplemental Content

Loading ...
Support Center